Risk Factors Update Summary

• Accumulated deficit increased from $542 million to $849 million, impacting future profitability and funding.
• New and emerging data privacy regimes, such as China's PIPL, may impact operations globally.
• Cash, cash equivalents, and marketable securities decreased from $866 million to $1.14 billion.
• Clinical trials' timing and cost impacted by geopolitical instability, public health epidemics, and competition.
• Potential legal challenges to mechanisms for transferring personal data could disrupt operations.
• Anticipated cash position to fund operations extended from 2026 to 2027, but uncertain additional capital.
• Preliminary and interim data subject to audit, with potential material changes affecting business prospects.
• Phase 3 trials initiated by competitors may affect development programs and stock price fluctuation.
• Increased scrutiny on data privacy could lead to regulatory actions, fines, and penalties.
• Future capital requirements dependent on various factors, including regulatory review costs and commercialization expenses.